NSAIDs Rx class labeling should reflect recent GI risk research -- Arthritis Advisory Cmte.
This article was originally published in The Tan Sheet
Executive Summary
Rx NSAID GASTROPATHY CLASS WARNING UPDATE ADVISED to reflect current research on gastrointestinal (GI) risks posed by prescription nonsteroidal anti-inflammatory drugs, FDA's Arthritis Advisory Committee unanimously recommended at its Oct. 12 meeting. The meeting was structured as an open forum for suggestions from the committee and guests. The discussion, however, was limited to physician labeling of Rx NSAIDs.